You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 460 Efficacy of adding anti-PD1 immunotherapy to dabrafenib + trametinib (DT) at progression in BRAFv600e mutated anaplastic thyroid carcinoma (BRAFm-ATC)

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
460 Efficacy of adding anti-PD1 immunotherapy to dabrafenib + trametinib (DT) at progression in BRAFv600e mutated anaplastic thyroid carcinoma (BRAFm-ATC)

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023156013
Dec 202361016
Jan 20242805
Feb 20242603
Mar 20243605
Apr 20242006
May 20241003
Jun 20242205
Jul 20241003
Aug 20242604
Sep 20241801
Oct 20241401
Nov 20241804
Dec 2024203
Jan 20251008
Feb 2025203
Mar 20250010
Apr 2025008
May 2025004
Jun 2025005
Total4590110